Ibogaine will become the central contested exhibit in the 2026-2027 psychedelic safety culture war, simultaneously weaponized by pro-regulation and anti-prohibition advocates

The QT prolongation and arrhythmia data is clinically real and clinically manageable — but that nuance will be stripped in translation. The structural conditions for a bifurcated narrative are already in place: veterans' groups have a compelling human-interest frame around ibogaine's anti-addiction properties; anti-drug advocates have equally compelling mortality data. The 2023 Stanford/VA ibogaine veteran study was already generating divergent coverage before today's cardiac papers. With CMPS down 6.8% and ATAI down 4.2% on the same day these papers dropped, market participants are reading this as net-negative — which will itself become a data point in how journalists frame the story. The prediction is not that this debate will be resolved, but that ibogaine will occupy the contested center of the psychedelic policy argument through at least mid-2027, when an FDA advisory committee revi